ImmuCell(ICCC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total product sales for 2025 reached $27.6 million, representing a 4.3% increase compared to 2024 [4][8] - Net operating profit improved by $3.3 million to $1.6 million in 2025, driven by expanded gross margins [4][14] - Gross margin for Q4 2025 was 38%, up from 37% in Q4 2024, while the full year gross margin increased to 41% from 30% in 2024 [9][10] - Net loss for 2025 was $1 million, a $1.1 million improvement from 2024, with basic net loss per share improving to approximately $0.12 from $0.26 [13][14] Business Line Data and Key Metrics Changes - Domestic sales in Q4 2025 grew by 8.7% to $7 million, while international sales declined to about $600,000, primarily due to order timing [8][9] - The product mix showed a shift towards Tri-Shield, indicating new customer acquisition and migration from lower-priced products [9] Market Data and Key Metrics Changes - The U.S. market for calf scours prevention products saw a 14% increase in spending to approximately $93 million in 2025 [17][18] - Despite the growth, about 55% of calves still do not receive any treatment for scours, indicating a significant addressable market of over $200 million in the U.S. alone [18] Company Strategy and Development Direction - The company has pivoted to focus on maximizing shareholder value from the First Defense franchise, which is positioned in a growing market for calf health solutions [4][5] - Manufacturing capacity has been increased from approximately 3 million units in 2023 to 4.6 million units in 2025, with plans to further expand capacity to between 5 and 6 million units [19][20] - The company has paused investment in a subclinical mastitis product to concentrate on the scours market opportunity and improve manufacturing capabilities [19][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth due to increased manufacturing capacity and a proactive approach to customer acquisition [19][26] - The company aims to address challenges related to yield improvement and capacity expansion while focusing on top-line growth [25][26] Other Important Information - A non-cash write-down of approximately $650,000 was taken in Q3 and Q4 2025, primarily related to inventory [10][12] - Operating expenses increased to $3 million in Q4 2025, driven by higher general and administrative costs [11] Q&A Session Summary Question: What are the biggest challenges ahead for the company to achieve its goals? - Management identified challenges related to planned yield increases and capacity expansion, emphasizing the need for proactive customer outreach [25][26] Question: Will there be any additional Re-Tain write-downs in 2026? - Management does not anticipate large write-downs for Re-Tain assets, with a modest salvage value already booked [27] Question: How much of 2025 revenue is considered recurring? - Management noted high customer loyalty and satisfaction, but could not provide exact churn calculations due to past supply constraints [28][30]